PH-10: Completed Phase IIc enrollment

Provectus completed enrollment of more than 90 patients in a single-blind, placebo-controlled, U.S. Phase IIc trial evaluating topical 0.002%, 0.005% and 0.01% formulations of once-daily PH-10 for 28 ...